NO320713B1 - Farmasoytisk preparat som omfatter Sertoli-celler og celler som produserer en biologisk faktor, seksjonert sett med beholdere for cellene, produktartikkel som omfatter et embaleringsmateriale med Sertoli-celler og fremgangsmate for okning av utvinning og profilering av celler ex vivo. - Google Patents
Farmasoytisk preparat som omfatter Sertoli-celler og celler som produserer en biologisk faktor, seksjonert sett med beholdere for cellene, produktartikkel som omfatter et embaleringsmateriale med Sertoli-celler og fremgangsmate for okning av utvinning og profilering av celler ex vivo. Download PDFInfo
- Publication number
- NO320713B1 NO320713B1 NO19964342A NO964342A NO320713B1 NO 320713 B1 NO320713 B1 NO 320713B1 NO 19964342 A NO19964342 A NO 19964342A NO 964342 A NO964342 A NO 964342A NO 320713 B1 NO320713 B1 NO 320713B1
- Authority
- NO
- Norway
- Prior art keywords
- cells
- sertoli
- sertoli cells
- rats
- islets
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 title claims abstract description 134
- 210000000717 sertoli cell Anatomy 0.000 title claims abstract description 121
- 238000000034 method Methods 0.000 title claims abstract description 37
- 239000003181 biological factor Substances 0.000 title claims abstract description 35
- 239000005022 packaging material Substances 0.000 title claims description 14
- 238000011084 recovery Methods 0.000 title claims description 14
- 230000001965 increasing effect Effects 0.000 title claims description 13
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 6
- 241000124008 Mammalia Species 0.000 claims abstract description 45
- 201000010099 disease Diseases 0.000 claims abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 21
- 210000001821 langerhans cell Anatomy 0.000 claims abstract description 6
- 210000000496 pancreas Anatomy 0.000 claims description 25
- 230000035755 proliferation Effects 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 7
- 229940088597 hormone Drugs 0.000 claims description 7
- 239000005556 hormone Substances 0.000 claims description 7
- 230000002950 deficient Effects 0.000 claims description 6
- 238000003501 co-culture Methods 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 73
- 210000004153 islets of langerhan Anatomy 0.000 abstract description 37
- 230000001413 cellular effect Effects 0.000 abstract description 2
- 230000007812 deficiency Effects 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 108
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 67
- 238000002054 transplantation Methods 0.000 description 59
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 50
- 239000008103 glucose Substances 0.000 description 50
- 210000001519 tissue Anatomy 0.000 description 35
- 102000004877 Insulin Human genes 0.000 description 33
- 108090001061 Insulin Proteins 0.000 description 33
- 229940125396 insulin Drugs 0.000 description 33
- 230000004044 response Effects 0.000 description 27
- 238000012360 testing method Methods 0.000 description 24
- 210000002700 urine Anatomy 0.000 description 22
- 230000001019 normoglycemic effect Effects 0.000 description 19
- 210000001550 testis Anatomy 0.000 description 19
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 18
- 230000037396 body weight Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 108010036949 Cyclosporine Proteins 0.000 description 16
- 229960001265 ciclosporin Drugs 0.000 description 16
- 229930182912 cyclosporin Natural products 0.000 description 16
- 238000012453 sprague-dawley rat model Methods 0.000 description 16
- 238000005119 centrifugation Methods 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 210000000056 organ Anatomy 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 14
- 102000029816 Collagenase Human genes 0.000 description 13
- 108060005980 Collagenase Proteins 0.000 description 13
- 229960002424 collagenase Drugs 0.000 description 13
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 12
- 108010075254 C-Peptide Proteins 0.000 description 12
- 201000001421 hyperglycemia Diseases 0.000 description 12
- 238000005138 cryopreservation Methods 0.000 description 11
- 239000003018 immunosuppressive agent Substances 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 241000282693 Cercopithecidae Species 0.000 description 8
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 229940125721 immunosuppressive agent Drugs 0.000 description 8
- 230000007774 longterm Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 238000010257 thawing Methods 0.000 description 8
- 102000016911 Deoxyribonucleases Human genes 0.000 description 7
- 108010053770 Deoxyribonucleases Proteins 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 206010062016 Immunosuppression Diseases 0.000 description 7
- 230000001506 immunosuppresive effect Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004602 germ cell Anatomy 0.000 description 6
- 238000002513 implantation Methods 0.000 description 6
- 210000002332 leydig cell Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 230000002381 testicular Effects 0.000 description 6
- 102000051325 Glucagon Human genes 0.000 description 5
- 108060003199 Glucagon Proteins 0.000 description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000001493 electron microscopy Methods 0.000 description 5
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 5
- 229960004666 glucagon Drugs 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 229940122199 Insulin secretagogue Drugs 0.000 description 4
- 208000007976 Ketosis Diseases 0.000 description 4
- 108010067035 Pancrelipase Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 4
- 229960001381 glipizide Drugs 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000003914 insulin secretion Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000012916 structural analysis Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 208000017667 Chronic Disease Diseases 0.000 description 3
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 3
- 229920001917 Ficoll Polymers 0.000 description 3
- 108010003272 Hyaluronate lyase Proteins 0.000 description 3
- 102000001974 Hyaluronidases Human genes 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 229960002773 hyaluronidase Drugs 0.000 description 3
- 230000003345 hyperglycaemic effect Effects 0.000 description 3
- 229940124589 immunosuppressive drug Drugs 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- UOFGSWVZMUXXIY-UHFFFAOYSA-N 1,5-Diphenyl-3-thiocarbazone Chemical compound C=1C=CC=CC=1N=NC(=S)NNC1=CC=CC=C1 UOFGSWVZMUXXIY-UHFFFAOYSA-N 0.000 description 2
- 241000501754 Astronotus ocellatus Species 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010023379 Ketoacidosis Diseases 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 125000005909 ethyl alcohol group Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006362 insulin response pathway Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000013059 nephrectomy Methods 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- 239000012285 osmium tetroxide Substances 0.000 description 2
- 239000000088 plastic resin Substances 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 210000004739 secretory vesicle Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 229960001967 tacrolimus Drugs 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- 229950003937 tolonium Drugs 0.000 description 2
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000031872 Body Remains Diseases 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 101710186630 Insulin-1 Proteins 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010005991 Pork Regular Insulin Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- -1 coatings Substances 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000000494 inguinal canal Anatomy 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000004140 ketosis Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- 229960002455 methoxyflurane Drugs 0.000 description 1
- 238000011169 microbiological contamination Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004188 regulation of glucose levels Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002863 seminiferous tubule Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0683—Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
- C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/24—Genital tract cells, non-germinal cells from gonads
- C12N2502/246—Cells of the male genital tract, non-germinal testis cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21169594A | 1994-04-13 | 1994-04-13 | |
| PCT/US1995/004565 WO1995028167A1 (fr) | 1994-04-13 | 1995-04-13 | Procedes de traitement de maladies a l'aide de cellules de sertoli et des allogreffes ou xenogreffes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO964342D0 NO964342D0 (no) | 1996-10-11 |
| NO964342L NO964342L (no) | 1996-12-13 |
| NO320713B1 true NO320713B1 (no) | 2006-01-23 |
Family
ID=22787974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19964342A NO320713B1 (no) | 1994-04-13 | 1996-10-11 | Farmasoytisk preparat som omfatter Sertoli-celler og celler som produserer en biologisk faktor, seksjonert sett med beholdere for cellene, produktartikkel som omfatter et embaleringsmateriale med Sertoli-celler og fremgangsmate for okning av utvinning og profilering av celler ex vivo. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US5725854A (fr) |
| EP (1) | EP0755258B1 (fr) |
| JP (1) | JPH09512015A (fr) |
| AT (1) | ATE212230T1 (fr) |
| AU (1) | AU715177B2 (fr) |
| CA (1) | CA2187803C (fr) |
| DE (1) | DE69525151T2 (fr) |
| DK (1) | DK0755258T3 (fr) |
| ES (1) | ES2169128T3 (fr) |
| FI (2) | FI120670B (fr) |
| NO (1) | NO320713B1 (fr) |
| WO (1) | WO1995028167A1 (fr) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE216576T1 (de) * | 1995-02-08 | 2002-05-15 | Yamanouchi Europ Bv | Vehrfahren zur herstellung von beta-lactam antibiotikum enthaltenden oralen dosisformen |
| EP0814819B1 (fr) * | 1995-03-13 | 2004-07-14 | University Of South Florida | Cellules de sertoli employees comme facilitateur de transplantation cellulaire |
| US5702700A (en) * | 1995-03-13 | 1997-12-30 | University Of South Florida | Sertoli cells as neurorecovery inducing cells for Parkinson's disease |
| US5830460A (en) * | 1995-03-13 | 1998-11-03 | University Of South Florida | Sertoli cells as transplantation facilitator for cell transplantation |
| WO1996033264A1 (fr) * | 1995-04-20 | 1996-10-24 | University Of South Florida | Agregat de cellules de sertoli purifiees et isolees |
| US6037175A (en) * | 1996-03-12 | 2000-03-14 | The University Of South Florida | Method and media for enhancing cryopreservation of cells |
| EP1044024A1 (fr) * | 1998-01-02 | 2000-10-18 | Titan Pharmaceuticals, Inc. | Utilisation de cellules epitheliales retiniennes pigmentees pour la creation d'un site d'acception immunitaire |
| ES2338076T3 (es) * | 1998-11-06 | 2010-05-03 | Sertoli Technologies, Inc. | Produccion de un factor biologico y creacion de un entorno inmunologicamente privilegiado usando celulas de sertoli alteradas geneticamente. |
| US7399751B2 (en) * | 1999-11-04 | 2008-07-15 | Sertoli Technologies, Inc. | Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells |
| ES2270626T3 (es) | 1998-12-15 | 2007-04-01 | Universidad Nacional Autonoma De Mexico | Procedimiento y dispositivo para favorecer el implante material biologico. |
| US6365385B1 (en) | 1999-03-22 | 2002-04-02 | Duke University | Methods of culturing and encapsulating pancreatic islet cells |
| US6303355B1 (en) | 1999-03-22 | 2001-10-16 | Duke University | Method of culturing, cryopreserving and encapsulating pancreatic islet cells |
| US7115256B1 (en) * | 1999-04-09 | 2006-10-03 | Titan Pharmaceuticals, Inc. | Methods of treating schizophrenia |
| US7122177B2 (en) | 2000-01-20 | 2006-10-17 | Diabcell Pty Ltd. | Preparation and xenotransplantation of porcine islets |
| US6790441B1 (en) | 2000-06-13 | 2004-09-14 | University Of South Florida | Sertoli cells as biochambers |
| AU9118201A (en) | 2000-09-20 | 2002-04-02 | Islet Sheet Medical Llc | Improved methods for fabrication of thin sheet bio-artificial organs |
| AU2002305079B8 (en) * | 2001-05-11 | 2006-05-25 | Ortho-Mcneil Pharmaceutical, Inc. | Immune modulation device for use in animals |
| ATE535601T1 (de) * | 2001-09-28 | 2011-12-15 | Diabcell Pty Ltd | Züchtung von fremdtransplantationsmaterial in kultur |
| RU2315621C2 (ru) * | 2002-02-22 | 2008-01-27 | Профи Мед Аб | Применение ингибитора или антагониста тканевого фактора |
| US20040062753A1 (en) * | 2002-09-27 | 2004-04-01 | Alireza Rezania | Composite scaffolds seeded with mammalian cells |
| EP1636346A4 (fr) * | 2003-06-24 | 2007-03-28 | Diabcell Pty Ltd | Ilots porcins cultives avec des cellules de sertoli porcines pour la xenotransplantation |
| CA2848954A1 (fr) * | 2003-07-03 | 2005-03-03 | Sertoli Technologies, Llc | Compositions contenant des cellules de sertoli et des cellules myoides et leurs utilisations dans des greffes cellulaires |
| WO2006118564A2 (fr) * | 2004-04-29 | 2006-11-09 | Washington State University Research Foundation | Cellules modifiees exprimant une proteine modulant l'activite de proteines bhlh et utilisations de celles-ci |
| WO2006020288A2 (fr) | 2004-07-29 | 2006-02-23 | University Of Miami | Dispositif hybride pour therapies cellulaires |
| US20070065422A1 (en) * | 2005-09-20 | 2007-03-22 | Cameron Don F | Induction of immune tolerance by sertoli cells |
| WO2007089572A2 (fr) * | 2006-01-26 | 2007-08-09 | John Constance M | Cultures de cellules de sertoli humaines primaires proliférantes et leurs applications |
| JP2010500871A (ja) * | 2006-07-28 | 2010-01-14 | セルトセル・バイオテクノロジー・（ユーエス）・コーポレイション | 成熟セルトリ細胞およびその使用 |
| US9161901B2 (en) | 2008-02-21 | 2015-10-20 | University Of South Florida | Nanoparticle targeted drug delivery to the lungs using extra-testicular Sertoli cells |
| US8709400B2 (en) * | 2009-07-27 | 2014-04-29 | Washington University | Inducement of organogenetic tolerance for pancreatic xenotransplant |
| SG10202001012VA (en) | 2009-08-28 | 2020-04-29 | Sernova Corp | Device for cellular transplantation and uses thereof |
| MX2010013135A (es) | 2010-11-30 | 2012-05-31 | Val De Bio S De R L De C V | Procedimiento y dispositivo mejorados para favorecer el trasplante de material biológico. |
| US10532128B2 (en) | 2015-11-18 | 2020-01-14 | Viera Bioscience, Inc. | Implantable cellular therapy device for treatment of graft versus host disease and tolerance induction |
| EP3697469A4 (fr) | 2017-10-17 | 2021-09-22 | The Methodist Hospital System | Dispositifs d'administration |
| EP3962505A1 (fr) | 2019-05-01 | 2022-03-09 | Sernova Corporation | Méthodes de traitement du diabète à l'aide de dispositifs pour transplantation cellulaire |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4829000A (en) * | 1985-08-30 | 1989-05-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Reconstituted basement membrane complex with biological activity |
| US5158874A (en) * | 1985-08-30 | 1992-10-27 | The United States Of America As Represented By The Department Of Health And Human Services | Determining metastic potential of tumor cells and isolating metastic tumor cells |
| US5053332A (en) * | 1989-07-24 | 1991-10-01 | Cook Richard B | Agarose beads, preferably incorporating biological materials |
| US5304603A (en) * | 1991-06-18 | 1994-04-19 | The Population Council | Leydig cell stimulator |
| DE4227066A1 (de) * | 1992-08-16 | 1994-02-17 | Bernhard Josef Dr Med Hering | Langerhans'sche Inseln in reiner Form |
| US5474905A (en) * | 1993-11-24 | 1995-12-12 | Research Corporation Technologies | Antibodies specific for streptococcus pneumoniae hemin/hemoglobin-binding antigens |
| US5849285A (en) * | 1994-04-13 | 1998-12-15 | Research Corporation Technologies, Inc. | Autoimmune disease treatment with sertoli cells and in vitro co-culture of mammal cells with sertoli cells |
-
1995
- 1995-04-13 DK DK95916368T patent/DK0755258T3/da active
- 1995-04-13 DE DE69525151T patent/DE69525151T2/de not_active Expired - Lifetime
- 1995-04-13 US US08/421,641 patent/US5725854A/en not_active Expired - Lifetime
- 1995-04-13 AU AU22893/95A patent/AU715177B2/en not_active Expired
- 1995-04-13 CA CA002187803A patent/CA2187803C/fr not_active Expired - Lifetime
- 1995-04-13 JP JP7527083A patent/JPH09512015A/ja active Pending
- 1995-04-13 WO PCT/US1995/004565 patent/WO1995028167A1/fr active Application Filing
- 1995-04-13 AT AT95916368T patent/ATE212230T1/de active
- 1995-04-13 ES ES95916368T patent/ES2169128T3/es not_active Expired - Lifetime
- 1995-04-13 EP EP95916368A patent/EP0755258B1/fr not_active Expired - Lifetime
- 1995-06-06 US US08/467,341 patent/US5843430A/en not_active Expired - Lifetime
- 1995-06-06 US US08/467,338 patent/US5759534A/en not_active Expired - Lifetime
-
1996
- 1996-10-08 FI FI964033A patent/FI120670B/fi not_active IP Right Cessation
- 1996-10-11 NO NO19964342A patent/NO320713B1/no not_active IP Right Cessation
-
2008
- 2008-07-18 FI FI20085733A patent/FI120696B/fi not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2187803A1 (fr) | 1995-10-26 |
| FI120670B (fi) | 2010-01-29 |
| US5759534A (en) | 1998-06-02 |
| FI20085733A (fi) | 2008-07-18 |
| DK0755258T3 (da) | 2002-05-13 |
| DE69525151T2 (de) | 2002-08-14 |
| CA2187803C (fr) | 1999-09-28 |
| FI120696B (fi) | 2010-01-29 |
| NO964342D0 (no) | 1996-10-11 |
| WO1995028167A1 (fr) | 1995-10-26 |
| FI964033A (fi) | 1996-12-12 |
| FI964033A0 (fi) | 1996-10-08 |
| NO964342L (no) | 1996-12-13 |
| ATE212230T1 (de) | 2002-02-15 |
| AU2289395A (en) | 1995-11-10 |
| ES2169128T3 (es) | 2002-07-01 |
| JPH09512015A (ja) | 1997-12-02 |
| US5725854A (en) | 1998-03-10 |
| DE69525151D1 (de) | 2002-03-14 |
| EP0755258B1 (fr) | 2002-01-23 |
| US5843430A (en) | 1998-12-01 |
| EP0755258A1 (fr) | 1997-01-29 |
| AU715177B2 (en) | 2000-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO320713B1 (no) | Farmasoytisk preparat som omfatter Sertoli-celler og celler som produserer en biologisk faktor, seksjonert sett med beholdere for cellene, produktartikkel som omfatter et embaleringsmateriale med Sertoli-celler og fremgangsmate for okning av utvinning og profilering av celler ex vivo. | |
| US5849285A (en) | Autoimmune disease treatment with sertoli cells and in vitro co-culture of mammal cells with sertoli cells | |
| JP3621106B2 (ja) | 機能的なランゲルハンス島のインビトロ培養およびそのインビボ使用 | |
| US5958404A (en) | Treatment methods for disease using co-localized cells and Sertoli cells obtained from a cell line | |
| Ballinger et al. | Transplantation of intact pancreatic islets in rats | |
| WARNock et al. | STUDIES OF THE ISOLATION AND VIABILITY OF HUMAN ISLETS OF LANGERHANS1, 2 | |
| KR19990067077A (ko) | 기능성 랑게르한스 섬의 시험관내 성장 및 그 생체내 사용방법 | |
| JPH11514877A (ja) | 機能性ランゲルハンス島のインビトロ成長およびそのインビボの使用 | |
| BROWN et al. | Pancreas transplantation for diabetes mellitus | |
| EP2216033B1 (fr) | Méthode de traitement d'une maladie par transplantation d'organes ou de tissus allogenes or xenogenes | |
| Lacy | Experimental immuno‐alteration | |
| Rajab et al. | Comparison of the portal vein and kidney subcapsule as sites for primate islet autotransplantation | |
| US20020065212A1 (en) | Methods of treating disease using sertoli cells and allografts or xenografts | |
| Inoue et al. | Isolation of adult pig islet: In vitro assessment and xenotransplantation | |
| Korsgren et al. | Porcine islet-like cell clusters cure diabetic nude rats when transplanted under the kidney capsule, but not when implanted into the liver or spleen | |
| Karl et al. | Transplantation of insulin-secreting tissues. | |
| Charles et al. | Storage and microencapsulation of islets for transplantation | |
| Miyamoto et al. | Development of a cryopreservation procedure employing a freezer bag for pancreatic islets using a newly developed cryoprotectant | |
| Peterson et al. | Human fetal pancreas transplants | |
| Andersson et al. | Structure and function of macroencapsulated human and rodent pancreatic islets transplanted into nude mice | |
| Peterson et al. | Fetal islet transplantation: implications for diabetes | |
| Walthall et al. | Rodent xenografts of human and porcine fetal tissue | |
| Maeno et al. | Islet-like cell clusters: viability, cell types, and subretinal transplantation in pancreatectomized cats | |
| Andersson et al. | Experimental studies of transplantation and regeneration of endocrine pancreatic cells | |
| Jovanovic-Peterson et al. | The Use of Human Fetal Islet Tissue for Adjunctive Treatment in Insulin-Dependent Diabetic Patients: The Case for “Partial Success” |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |